These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17576983)

  • 1. Health Canada's Progressive Licensing Framework.
    Yeates N; Lee DK; Maher M
    CMAJ; 2007 Jun; 176(13):1845-7. PubMed ID: 17576983
    [No Abstract]   [Full Text] [Related]  

  • 2. Progressive drug licensing: an opportunity to achieve transparency and accountability?
    Wright JM
    CMAJ; 2007 Jun; 176(13):1848-9. PubMed ID: 17576984
    [No Abstract]   [Full Text] [Related]  

  • 3. Progressive licensing needs progressive open debate.
    Hébert PC; Stanbrook M; Sibbald B; Flegel K; MacDonald N; Attaran A
    CMAJ; 2007 Jun; 176(13):1801, 1803. PubMed ID: 17576971
    [No Abstract]   [Full Text] [Related]  

  • 4. Can Health Canada protect Canadians from unsafe drugs?
    Hébert PC; Stanbrook MB; MacDonald N; Flegel K; Coutts J; MacLeod S
    CMAJ; 2011 Jul; 183(10):1125-6. PubMed ID: 21502342
    [No Abstract]   [Full Text] [Related]  

  • 5. Health Canada targets postmarket surveillance of drugs.
    Sibbald B
    CMAJ; 2002 Jun; 166(12):1580. PubMed ID: 12074132
    [No Abstract]   [Full Text] [Related]  

  • 6. Health authorities and drug utilization studies.
    Garcia Alonso F; Scott AI; Stika L; Westerholm B
    WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 8. Canada's framework for health promotion and chronic illness.
    Naegele B
    WHO Reg Publ Eur Ser; 1992; 44():229-31. PubMed ID: 1514974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requests approaching 50,000 annually for emergency drug release program.
    Robinson A
    CMAJ; 1995 Sep; 153(5):665-6. PubMed ID: 7641166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importing medicines with quality assurance].
    Agência Nacional de Vigilância Sanitária - Anvisa
    Rev Saude Publica; 2004 Apr; 38(2):337-8. PubMed ID: 15122397
    [No Abstract]   [Full Text] [Related]  

  • 11. Responsibility for pharmaceutical company samples.
    Reti S
    N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193
    [No Abstract]   [Full Text] [Related]  

  • 12. Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.
    Olmo CA; McGettigan P; Kurz X
    Clin Pharmacol Ther; 2019 Jul; 106(1):39-42. PubMed ID: 30970160
    [No Abstract]   [Full Text] [Related]  

  • 13. The need to improve hospital investigational drug policies and procedures.
    Stolar MH
    Hosp Formul; 1983 Jan; 18(1):79-82. PubMed ID: 10258324
    [No Abstract]   [Full Text] [Related]  

  • 14. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
    Lim RR
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.
    Laupacis A; Paterson JM; Mamdani M; Rostom A; Anderson GM
    CMAJ; 2003 Nov; 169(11):1167-70. PubMed ID: 14638652
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to "The common drug review: a NICE start for Canada?".
    Lee KM; la Fleur DP
    Health Policy; 2007 Jan; 80(1):1. PubMed ID: 16597473
    [No Abstract]   [Full Text] [Related]  

  • 17. Sharing the cost: health information licensing programmes in Canada.
    Stieda V; Bacić M
    Health Info Libr J; 2009 Dec; 26(4):322-30. PubMed ID: 19930480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory.
    Meena J; Sood S; Rani N; Bisht R; Kiran M; Chhabra R; Singh S; Chand S
    Biologicals; 2019 May; 59():72-73. PubMed ID: 30917901
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug regulation in Spain].
    Rubio Terrés C
    Med Clin (Barc); 1992 May; 98(19):741-8. PubMed ID: 1608280
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
    Kravitz RL; Bell RA
    Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.